{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:57:33Z","timestamp":1773712653996,"version":"3.50.1"},"posted":{"date-parts":[[2024,11,2]]},"group-title":"Neurology","reference-count":37,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>All individuals with Down Syndrome (DS) will develop full-blown Alzheime\u0155s disease (AD) pathology by age 40, decades before the occurrence of sporadic late-onset AD. Understanding this strong biological relation between age and AD pathology risk in DS is important to accelerate diagnostics, disease monitoring, and treatment. Several genes encoded in chromosome 21 including dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) have been proven to contribute to the pathology. A recently validated plasma immunoassay to measure tau phosphorylation at threonine-212 (p-tau212) has very high diagnostic accuracy in detecting AD. P-tau212 is also very sensitive to DYRK1A phosphorylation and is increased in DSAD brain lysates. Here, we assessed the potential of this biomarker in DSAD and sporadic AD.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using Simoa technology, we tested p-tau212 and p-tau181 (n=245 for plasma, n=114 matching cerebrospinal fluid (CSF) samples). We used AUC-ROC to examine diagnostic performance and the DeLong test to compare the AUC-ROC differences between methods. Spearman correlation is used to examine correlations. Fold changes relative to median levels were calculated for their respective asymptomatic groups. ANCOVA followed by Tukey post-hoc test was used to calculate differences across groups. LOESS was used to determine the temporality of plasma biomarker changes.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We have confirmed that p-tau212 has extremely high accuracy in detecting AD-related changes in euploid controls. For the DS population, we observed a strong correlation between plasma and CSF p-tau212 (r=0.867; p&lt;0.001). In prodromal DS (pDS) and dementia DS (dDS), we observed significantly elevated levels of p-tau212 in reference to asymptomatic DS (aDS). The diagnostic accuracy to differentiate between aDS and dDS was AUC=0.91 and AUC = 0.86 in discriminating between DS amyloid positive and amyloid negative participants. Plasma p-tau212 started increasing approximately when people became amyloid PET-positive.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We have confirmed that the levels of plasma p-tau212 are increased in the DS population and sporadic AD cases including prodromal and MCI states. Plasma p-tau212 might have utility for theragnostic, monitoring therapy efficacy, and as a target engagement biomarker in clinical trials both in sporadic and DSAD.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.10.31.24316469","type":"posted-content","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T17:40:18Z","timestamp":1730569218000},"source":"Crossref","is-referenced-by-count":4,"title":["Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer\u2019s disease"],"prefix":"10.64898","author":[{"given":"Przemys\u0142aw R.","family":"Kac","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Montoliu-Gaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Lantero Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Maure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Gonz\u00e1lez-Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bessy","family":"Benejam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Turton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Barroeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Videla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Carmona-Iragui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"issue":"11","key":"2024110600500830000_2024.10.31.24316469v1.1","first-page":"1721","article-title":"[Study of somatic chromosomes from 9 mongoloid children]","volume":"248","year":"1959","journal-title":"Comptes Rendus Hebd Seances Acad Sci"},{"key":"2024110600500830000_2024.10.31.24316469v1.2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410170310"},{"key":"2024110600500830000_2024.10.31.24316469v1.3","doi-asserted-by":"publisher","DOI":"10.1111\/jir.12390"},{"key":"2024110600500830000_2024.10.31.24316469v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00245-3"},{"key":"2024110600500830000_2024.10.31.24316469v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00063-6"},{"key":"2024110600500830000_2024.10.31.24316469v1.6","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddl437"},{"key":"2024110600500830000_2024.10.31.24316469v1.7","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12648"},{"key":"2024110600500830000_2024.10.31.24316469v1.8","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e318202bfa1"},{"key":"2024110600500830000_2024.10.31.24316469v1.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2006.05217.x"},{"key":"2024110600500830000_2024.10.31.24316469v1.10","doi-asserted-by":"crossref","unstructured":"Duchon A , Herault Y. DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome. Front Behav Neurosci [Internet]. 2016 [cited 2021 Jul 14];10. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fnbeh.2016.00104\/full#B228","DOI":"10.3389\/fnbeh.2016.00104"},{"key":"2024110600500830000_2024.10.31.24316469v1.11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M301769200"},{"key":"2024110600500830000_2024.10.31.24316469v1.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2010.06769.x"},{"key":"2024110600500830000_2024.10.31.24316469v1.13","doi-asserted-by":"publisher","DOI":"10.1042\/bj3550609"},{"key":"2024110600500830000_2024.10.31.24316469v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30285-0"},{"key":"2024110600500830000_2024.10.31.24316469v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30689-9"},{"key":"2024110600500830000_2024.10.31.24316469v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30071-5"},{"key":"2024110600500830000_2024.10.31.24316469v1.17","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2020.12134"},{"issue":"5","key":"2024110600500830000_2024.10.31.24316469v1.18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","year":"2021","journal-title":"Acta Neuropathol (Berl)"},{"issue":"1","key":"2024110600500830000_2024.10.31.24316469v1.19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13195-022-01011-w","article-title":"Diagnostic value of serum versus plasma phospho-tau for Alzheimer\u2019s disease","volume":"14","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"2024110600500830000_2024.10.31.24316469v1.20","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00605-8"},{"issue":"6","key":"2024110600500830000_2024.10.31.24316469v1.21","doi-asserted-by":"crossref","first-page":"e14022","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"1","key":"2024110600500830000_2024.10.31.24316469v1.22","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/s41467-024-46876-7","article-title":"Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer\u2019s disease neuropathology","volume":"15","year":"2024","journal-title":"Nat Commun"},{"key":"2024110600500830000_2024.10.31.24316469v1.23","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-104539"},{"key":"2024110600500830000_2024.10.31.24316469v1.24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.110957"},{"issue":"6","key":"2024110600500830000_2024.10.31.24316469v1.25","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/alz.12463","article-title":"Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model","volume":"18","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2024110600500830000_2024.10.31.24316469v1.26","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-005-2483-9"},{"key":"2024110600500830000_2024.10.31.24316469v1.27","first-page":"597","article-title":"The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders","volume":"5","year":"2019","journal-title":"Alzheimers Dement N Y N"},{"issue":"9","key":"2024110600500830000_2024.10.31.24316469v1.28","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/acn3.50873","article-title":"Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse","volume":"6","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"2024110600500830000_2024.10.31.24316469v1.29","doi-asserted-by":"crossref","first-page":"e2212910","DOI":"10.1001\/jamanetworkopen.2022.12910","article-title":"Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome","volume":"5","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024110600500830000_2024.10.31.24316469v1.30","doi-asserted-by":"crossref","first-page":"104547","DOI":"10.1016\/j.ebiom.2023.104547","article-title":"Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study","volume":"90","year":"2023","journal-title":"eBioMedicine"},{"issue":"8","key":"2024110600500830000_2024.10.31.24316469v1.31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamaneurol.2022.1740","article-title":"Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers","volume":"79","year":"2022","journal-title":"JAMA Neurol"},{"key":"2024110600500830000_2024.10.31.24316469v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24319-x"},{"key":"2024110600500830000_2024.10.31.24316469v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0132-6"},{"issue":"16","key":"2024110600500830000_2024.10.31.24316469v1.34","doi-asserted-by":"crossref","first-page":"9355","DOI":"10.3390\/ijms23169355","article-title":"The Omnipresence of DYRK1A in Human Diseases","volume":"23","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024110600500830000_2024.10.31.24316469v1.35","doi-asserted-by":"crossref","first-page":"1391564","DOI":"10.3389\/fnmol.2024.1391564","article-title":"Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions","volume":"17","year":"2024","journal-title":"Front Mol Neurosci"},{"key":"2024110600500830000_2024.10.31.24316469v1.36","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201300325"},{"issue":"15","key":"2024110600500830000_2024.10.31.24316469v1.37","doi-asserted-by":"crossref","first-page":"12571","DOI":"10.1021\/acs.jmedchem.4c00483","article-title":"Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer\u2019s Disease","volume":"67","year":"2024","journal-title":"J Med Chem"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.10.31.24316469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:19:05Z","timestamp":1768508345000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.10.31.24316469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1101\/2024.10.31.24316469","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1002\/alz.70172","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,11,2]]},"subtype":"preprint"}}